3. There are currently 26 million people worldwide with Alzheimer’s disease. This figure is projected to grow to more than 106 million people by 2050. More than 5 million Americans are believed to have Alzheimer’s disease and by 2050, the number could increase to 15 million. Approximately 350,000 new cases of Alzheimer's disease are diagnosed each year. Alzheimer’s disease is the most common form of dementia (represents about 60% of the cases of dementia in the elderly). Death from Alzheimer’s disease is often underreported or misdiagnosed.

4. “Alzheimer's disease (AD) is chronic, progressive, age-related, non- reversible and incurable (to date) brain disorder that develops over a period of years and ultimately leads to a severe loss of mental function. Alzheimer's disease (AD) gradually results in cognitive impairments that leave patients completely dependent on others.”

5. “Until today, Alzheimer’s disease cannot be definitively diagnosed until after death, when a brain autopsy is performed on a patient and evidence of beta-amyloid plaque deposits and NFTs are found.”

6. “In AD, the development of pathology in the brain is thought to precede cognitive symptoms and, hence, diagnosis of the disease, by many years. Therefore, preclinical diagnosis of Alzheimer’s disease is one of the major challenges for the prevention of AD.”

7. Dce MRI CTSPECT PETX Ray MRI Structural imaging Functional imaging

8. “CT scans and MRIs only detect structural or anatomical changes in the brain and detection of subtle pathophysiological change in the brain at asymptomatic stages is not possible with MRI and CT scan especially when there is no evidence of anatomic changes.”

9. “Early diagnosis of Alzheimer’s disease might enable effective treatment before so many brain cells are lost through the disease. Therefore, it is important to identify non-demented individuals in the preclinical stage of AD, who are at very high risk for developing dementia.”

10. “Brain imaging, PET amyloid imaging in particular, when combined with the specific biomarkers, greatly increases one’s ability to predict who is at risk of developing AD several years before disease onset. It is now widely believed that β-Amyloid (Aβ) imaging has great potential to aid in the diagnosis of Alzheimer disease and the development of related therapeutics.”

11. “Positron emission tomography, also called PET imaging or a PET scan or nuclear medicine scan, is a type of nuclear medicine imaging which produces 3-dimensional, color images of the functional processes within the human body or brain.”

12. “Positron emission tomography (PET) is a method of medical imaging which allows displaying metabolic activity in a slice of the body by means of detecting radiation, emitted from a radio-isotope injected into the patient’s body.”

13. Today, a whole-body PET scan provides information about the body’s chemistry and cell function (metabolism) rather than pictures of the body’s anatomy or structure as shown by X-ray, ultrasound, CT scans, or MRI. As a result, PET scans may reveal abnormalities or tumors that would otherwise go undetected.

14. 1975 the first commercial PET scanner was introduced 70s and 80s PET was mainly used for research 1990s being used in clinics regularly

15. “PET is an imaging technique that can quantify increases in nerve cell activity in selective regions of the specific part of the body such as brain. PET scans use a small amount of a radioactive drug, or tracer, to show differences between healthy tissue and diseased tissue.”

16. “As the origins of many diseases are biochemical in nature, these functional changes often predate or exceed structural change in tissue or organs. PET enables physicians to assess chemical or physiological changes related to metabolism.”

17. Alzheimer's disease Mobility disorders Neurological disorders e.g. epilepsy Lung pathologies PET uses Neoplasms Visual cortex

18. Radiotracer injection Positron emission & annihilation Image production (reconstruction) 1 2 3

19. “PET scanning uses artificial radioactive tracers and radionuclides. Their lifetime is usually rather short, thus they need to be produced on site. PET tracers mimic the natural sugars, water, proteins, and oxygen found in our bodies. These tracers are injected into a patient and collect in various tissues and organs.”

20. “A metabolically active tracer, a biologic molecule that carries with it a positron emitting isotope is inserted in the body. Over a few minutes the isotope accumulates in an area of the body for which the molecule has an affinity. i.e. glucose labeled with 11 C or glucose analogue labeled with 18 F, accumulates in the brain or tumors, where glucose is used as the primary source of energy.”

21. “The radioactive nuclei then decay by positron emission as a nuclear proton changes into a positive electron and a neutron. The ejected positron combines with an electron instantaneously, and these 2 particles undergo the process of annihilation. The energy associated with the masses of the positron and electron is divided equally between 2 photons which fly away from one another at 180 0 angle. Each photon has an energy of 511 keV. These high energy gamma rays emerge from the body in opposite directions and recorded simultaneously by pair of detectors. “

22. “After 100,000 or more annihilation events are detected, the distribution of the positron-emitting tracer is calculated by tomographic reconstruction procedures. PET reconstructs a 2 dimensional image of cellular biological activities from the one dimensional projections seen at different angles. 3-D reconstructions can be done using 2D projections from multiple angles.”

24. Pathological marker Radioligand (radiotracer) Amyloid plaques18F-FDNNP 11C-PIB 18F-BAY94-9172 18F-AV-144 11C-SB13 18F-BF-227

25. PIB (Pittsburgh Compound B ) Short (20.4-min) radioactive half-life Higher dose is required

26. FDG (2-[18F] fluoro-2-deoxy-D-Glucose) In very early disease, the scans may be normal or equivocal. accuracy declines in the very elderly patient.

27. 18F-BAY94-9172 Significantly longer half life ( 109.4 m) Has shown high affinity and specificity for Aβ in vitro and binding to Amyloid plaques. Can distinguish subjects with AD from healthy elderly subjects and subjects with frontotemporal dementia

29. Correct diagnosis Confirmed, accurate diagnosis Economical Fast diagnosis PET-Amyloid imaging Early diagnosis Safe & compliant

30. “The radioactive nuclei then decay by positron emission as a nuclear positron and electron is divided equally between 2 photons which fly away from one another at 180 0 angle. Each photon has an energy of 511 keV. These high energy gamma rays emerge from the body in opposite directions and recorded simultaneously by pair of detectors.”